Tazarotene heads for success in psoriasis

&

The full results of a double-blind, phase III study of tazarotene involving patients with psoriasis were presented at this year’s Dermatology Update [ Montreal, Canada; October 1995 ]. The data showed that tazarotene gel significantly reduced lesion development, compared with placebo, and was well tolerated. These results bode well for the new retinoid, which was submitted to the US FDA in June 1995 for marketing approval as a treatment for acne and psoriasis.